SOX transcription factors and glioma stem cells:Choosing between stemness and differentiation
作者机构：Laboratory for Human Molecular GeneticsInstitute of Molecular Genetics and Genetic EngineeringUniversity of BelgradeBelgrade 11042Serbia Chair Biochemistry and Molecular BiologyFaculty of BiologyUniversity of BelgradeBelgrade 11158Serbia Department of Chemical and Biological SciencesSerbian Academy of Sciences and ArtsBelgrade 11000Serbia
出 版 物：《World Journal of Stem Cells》 (世界干细胞杂志（英文版）（电子版）)
年 卷 期：2021年第13卷第10期
页 面：1417-1445页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：Supported by Ministry of Education Science and Technological Development of the Republic of Serbia No.451-03-9/2021-14/200042
主 题：Glioblastoma SOX transcription factors Glioma stem cells Stemness Differentiation
摘 要：Glioblastoma(GBM)is the most common,most aggressive and deadliest brain ***,remarkable progress has been made towards understanding the cellular and molecular biology of *** tumor initiation,progression and relapse as well as resistance to treatments are associated with glioma stem cells(GSCs).GSCs exhibit a high proliferation rate and self-renewal capacity and the ability to differentiate into diverse cell types,generating a range of distinct cell types within the tumor,leading to cellular *** tumors may contain different subsets of GSCs,and some of them may adopt a quiescent state that protects them against chemotherapy and *** enriched in recurrent gliomas acquire more aggressive and therapy-resistant properties,making them more malignant,able to rapidly *** impact of SOX transcription factors(TFs)on brain tumors has been extensively studied in the last *** all SOX genes are expressed in GBM,and their expression levels are associated with patient prognosis and *** SOX TFs are involved in the maintenance of the stemness of GSCs or play a role in the initiation of GSC *** fine-tuning of SOX gene expression levels controls the balance between cell stemness and ***,innovative therapies targeting SOX TFs are emerging as promising tools for combatting *** GBM has been a demanding and challenging goal for *** current therapeutic strategies have not yet provided a cure for GBM and have only resulted in a slight improvement in patient *** approaches will require the fine adjustment of multimodal therapeutic strategies that simultaneously target numerous hallmarks of cancer cells to win the battle against GBM.
维普期刊数据库